Femasys Inc. announced the appointment of Todd A. Creech as Chief Financial Officer. Mr. Creech will serve as Femasys' principal financial and accounting officer, will report to Kathy Lee-Sepsick, President and CEO, and will be responsible for all financing, accounting, corporate development and investor activities. Mr. Creech previously served as the Chief Financial Officer of ZS Pharma Inc., from August 2013 until June 2015 and was part of the team responsible for taking the company public, completing a successful secondary offering, disseminating key clinical data, and positioning the company for M&A discussions and eventual acquisition.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.19 USD | +0.85% | -7.02% | +22.06% |
05-09 | Femasys Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-09 | Earnings Flash (FEMY) FEMASYS Reports Q1 Revenue $271,140 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.06% | 26.08M | |
-7.77% | 177B | |
-5.86% | 65.54B | |
-5.67% | 47.09B | |
+9.00% | 43.43B | |
+8.14% | 41.77B | |
+14.00% | 29.55B | |
+15.53% | 24.83B | |
-6.91% | 23.97B | |
-6.48% | 23.54B |
- Stock Market
- Equities
- FEMY Stock
- News Femasys Inc.
- Femasys Inc. Appoints Todd Creech as Chief Financial Officer